Gastrointestinal stromal tumour
Top Cited Papers
- 1 May 2007
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 369 (9574), 1731-1741
- https://doi.org/10.1016/s0140-6736(07)60780-6
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal TumorsAnnals of Surgery, 2006
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal Of Cancer, 2006
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal Of Cancer, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2004
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and StagingAnnals of Surgery, 1992